NGL Fine-Chem Ltd.
2,646.50
INR
+23.10
(+0.88%)
ISIN
INE887E01022
Return %
Stock
S&P 500
1Y
77.52
14.20
3Y
41.32
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Rahul Jayant Nachane
- Full Time Employees
- 502
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 301, E Square Mumbai MA India 400057
- IPO Date
- Dec 20, 1994
- Website
- nglfinechem.com
- Similar Companies
- Business
- NGL Fine-Chem Limited manufactures active pharmaceutical ingredients (APIs) and finished formulations for human and veterinary health applications, serving over 400 customers across more than 40 countries. Its core products include approximately 39 APIs—37 veterinary and 2 human APIs—covering anthelmintics, antiprotozoals, ectoparasiticides, and phosphorus supplements, along with intermediates and finished dosage forms. The company predominantly operates three cGMP-compliant manufacturing facilities near Mumbai, Maharashtra, focused on high-quality production with extensive in-house capabilities and backward integration. Founded in 1984 and headquartered in Navi Mumbai, NGL Fine-Chem leverages strong process development expertise, supported by modern research labs, kilo lab, and pilot plants. In the past two years, NGL Fine-Chem has pursued significant capacity expansions and strategic investments, including a Rs. 160 crore greenfield expansion at its Tarapur site to increase production capacity by 50%, expected to be completed in phases through 2026. This initiative is financed through debt and internal accruals, aiming to support new product pipelines and enhance market reach. The company has reported robust growth in net sales in recent quarters, driven by increased demand in its core veterinary pharmaceutical products, while maintaining a focus on cost efficiency and quality controls underpinned by ISO and WHO-GMP accreditations. NGL Fine-Chem continues to strengthen its operational footprint without major acquisitions, relying on organic growth and capex-heavy expansion to broaden its manufacturing capabilities. The company primarily targets animal health markets globally, with products catering to antiparasitic and phosphorous supplementation needs, alongside a smaller but growing human pharmaceuticals segment. Its offerings are designed to meet stringent regulatory standards across export markets. The firm emphasizes innovation in synthetic chemistry and scalable processes to serve multinational pharmaceutical clients effectively. NGL Fine-Chem operates as a publicly listed company on the NSE with the ticker NGLFINE.NS, continuing to focus on vertical integration to maintain competitive quality and pricing advantages. Overall, NGL Fine-Chem Limited stands as a specialized pharmaceutical manufacturer with a comprehensive portfolio of veterinary and human health APIs and formulations, underpinned by recent capacity expansions aimed at consolidating its market position and supporting product innovation through robust process development capabilities. Its operational base is concentrated in India, with a global customer outreach through exports to 40+ countries. The company remains committed to sustainable growth through enhancing production scale and maintaining high quality standards.